PLoS ONE (Jan 2020)

Plasma microRNAs biomarkers in mild cognitive impairment among patients with type 2 diabetes mellitus.

  • Iman I Salama,
  • Samia M Sami,
  • Ghada A Abdellatif,
  • Amira Mohsen,
  • Hanaa Rasmy,
  • Solaf Ahmed Kamel,
  • Mona Hamed Ibrahim,
  • Mona Mostafa,
  • Walaa A Fouad,
  • Hala M Raslan

DOI
https://doi.org/10.1371/journal.pone.0236453
Journal volume & issue
Vol. 15, no. 7
p. e0236453

Abstract

Read online

ObjectivesTo assess the potential value of some miRNAs as diagnostic biomarkers for mild cognitive impairment (MCI) among patients with type2 diabetes mellitus (T2DM) and to identify other risk factors for MCI among them.MethodsThis study enrolled 163 adults with T2DM using face to face interview. Cognitive function with its domains was assessed using Adenbrooke's Cognitive Examination III (ACE III). Lipid profile, glycated hemoglobin, and miR-128, miR-132, miR- 874, miR-134, miR-323, and miR-382 expressions, using quantitative real-time PCR, were assessed.ResultsMCI was detected among 59/163 (36.2%) patients with T2DM. Plasma expression of miR-132 was significantly higher in T2DM patients with MCI compared to those without MCI and to normal cognitive healthy individuals (median = 2, 1.1 and 1.2 respectively, P ConclusionMCI affects nearly one-third of adult patients with T2DM. A significantly over expression of miR-132 was detected among T2DM with MCI compared to those with normal cognition.